Stock exchange releases archive
 
 
Print
 

Stock Exchange Releases archive

Select year:
30.12.2008 Biotie's Financial Information in 2009
15.12.2008 Lundbeck announces start of new phase III clinical trials with nalmefene
17.11.2008 Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
14.11.2008 The acquisition of the pharmaceutical development company elbion GmbH completed
14.11.2008 Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp. held on November 14, 2008
12.11.2008 Biotie Therapies Corp. has published a listing prospectus
24.10.2008 Invitation to The Extraordinary General Meeting of Biotie Therapies Corp.
24.10.2008 Biotie to acquire CNS and inflammation specialist elbion GmbH
24.10.2008 Interim Report on Biotie Therapies Corp. January 1 - September 30, 2008
08.08.2008 Interim Report on Biotie Therapies Corp. January 1 - June 30, 2008
18.06.2008 Biotie's VAP-1 antibody program to proceed to clinical studies in rheumatoid arthritis and psoriasis patients
25.04.2008 Interim Report on Biotie Therapies Corp. January 1 - March 31, 2008
28.03.2008 Resolutions of the Annual General Meeting of Biotie Therapies Corp. held on March 28, 2008
26.03.2008 Addition to the Proposal to the Biotie Therapies Corp. Annual General Meeting convening on March 28, 2008
14.03.2008 Biotie Therapies Corp. Annual Report and Annual Summary 2007 published
29.02.2008 Invitation to the Annual General Meeting of Biotie Therapies Corp.
25.01.2008 Biotie Therapies Corp. Financial Statements Release January 1 - December 31, 2007
24.01.2008 Notification according to Chapter 2, Section 10 of the Securities Markets Act
07.01.2008 Tekes finances Biotie's Thrombosis program with EUR 1.7 million
02.01.2008 Nalmefene United Kingdom and Ireland rights acquired by Lundbeck